Aridis Pharmaceuticals
Company profile
Primary focus
Developing human-derived monoclonal antibody therapeutics and inhaled small-molecule anti-infectives for severe respiratory infections.
Why it’s included
The company develops multiple named monoclonal antibody therapeutics and inhaled small-molecule anti-infectives targeting ESKAPE pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, as evidenced by products like AR-401 and AR-301 and supporting patents and grants.
Relevant capabilities
- In vitro antibacterial and biofilm activity testing
- In vivo pulmonary infection models and efficacy testing
- Clinical trial design and execution (Phase I–III) for respiratory anti-infectives
- Formulation and inhalation delivery development for small-molecule anti-infectives
- Discovery of human monoclonal antibodies from convalescent patients
Commercial sectorAntibacterial Biologics & Immunotherapeutics
Technology classesMonoclonal antibodies targeting bacterial pathogens, Antivirulence agents (quorum sensing, toxin, biofilm), Novel antibiotic classes (non-beta-lactam)
Relevant commercial products
- Panaecin
- AR-501 (inhaled gallium citrate)
- AR-401
- AR-301
- AR-105
Relevant patents
3 families, 5 publications- Gallium formulation for the treatment and prevention of infectious diseases US-8637090-B2
- Human monoclonal antibody against S. aureus derived alpha-toxin and its use in treating or preventing abscess formation US-9249215-B2
- Targets of Acinetobacter baumannii US-10098942-B2